Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

cabazitaxel

  • You have access
    Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel
    YASUSHI NAKAI, KENTA ONISHI, YORIAKI KAGEBAYASHI, KEN FUJIMOTO, AKIHIDE HIRAYAMA, MASAKI HARAMOTO, ATSUSHI TOMIOKA, KENJI OTSUKA, EIJIRO OKAJIMA, TAKESHI OTANI, YOSHIHIRO MATSUMOTO, YUKINARI HOSOKAWA, MASAHIRO TANAKA, TOSHIHISA SAKA, NOBUO OYAMA, SHUYA HIRAO, KIYOHIDE FUJIMOTO and NOBUMICHI TANAKA
    Anticancer Research September 2025, 45 (9) 3953-3960; DOI: https://doi.org/10.21873/anticanres.17753
  • You have access
    The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer
    FUMIHIKO URABE, DAIGO KOBAYASHI, KOSUKE IWATANI, YU IMAI, HAJIME ONUMA, KOICHI AIKAWA, TAKAFUMI YANAGISAWA, KOJIRO TASHIRO, HIROSHI SASAKI, JUN MIKI, KENTA MIKI and TAKAHIRO KIMURA
    Anticancer Research October 2023, 43 (10) 4611-4617; DOI: https://doi.org/10.21873/anticanres.16655
  • You have access
    The CCL2–CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells
    ARIUNBOLD NATSAGDORJ, KOUJI IZUMI, KAORU HIRATSUKA, RENATO NAITO, SUGURU KADOMOTO, HIROAKI IWAMOTO, HIROSHI YAEGASHI, KAZUYOSHI SHIGEHARA, HIROKI NAKATA and ATSUSHI MIZOKAMI
    Anticancer Research June 2023, 43 (6) 2561-2569; DOI: https://doi.org/10.21873/anticanres.16423
  • Open Access
    Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice
    ATSUSHI MIZOKAMI, KOSHIRO NISHIMOTO, HIDEYASU MATSUYAMA, TOMOHIKO ICHIKAWA, SATORU TAKAHASHI, HIROAKI SHIINA, KATSUYOSHI HASHINE, YUTAKA SUGIYAMA, MANABU KAMIYAMA, HIDEKI ENOKIDA and KENICHI NAKAJIMA
    Anticancer Research March 2022, 42 (3) 1465-1475; DOI: https://doi.org/10.21873/anticanres.15617
  • You have access
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells
    HIROMITSU WATANABE, ASUKA KAWAKAMI, RYO SATO, KYOHEI WATANABE, YUTO MATSUSHITA and HIDEAKI MIYAKE
    Anticancer Research August 2021, 41 (8) 3753-3758; DOI: https://doi.org/10.21873/anticanres.15167
  • You have access
    Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
    PIRKKO-LIISA KELLOKUMPU-LEHTINEN, TIMO MARTTILA, ANTTI JEKUNEN, PETTERI HERVONEN, KATARIINA KLINTRUP, VESA KATAJA, TAPIO UTRIAINEN, MARJAANA LUUKKAA, MARKKU LESKINEN, KALEVI PULKKANEN, ANNA-LIISA KAUTIO and TEPPO HUTTUNEN
    Anticancer Research December 2020, 40 (12) 6915-6921; DOI: https://doi.org/10.21873/anticanres.14715
  • You have access
    YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression
    TAKESHI MIYAO, HIDEKAZU KOIKE, YOSHITAKA SEKINE, AKIRA OHTSU, DAISUKE OKA and KAZUHIRO SUZUKI
    Anticancer Research September 2020, 40 (9) 5091-5095; DOI: https://doi.org/10.21873/anticanres.14512
  • You have access
    Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer
    CHRISTINE VESTERGAARD MADSEN, PARVIN ADIMI, ANDERS JAKOBSEN and KARINA DAHL STEFFENSEN
    Anticancer Research September 2020, 40 (9) 5255-5261; DOI: https://doi.org/10.21873/anticanres.14529
  • You have access
    Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
    MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO
    Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957
  • You have access
    Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan
    SHOTARO YASUOKA, TAKESHI YUASA, MASAHIRO OGAWA, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, YUKIHIRO KONDO and JUNJI YONESE
    Anticancer Research October 2019, 39 (10) 5803-5809; DOI: https://doi.org/10.21873/anticanres.13784

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire